The linear progression through generations of BTK inhibitors may be a flawed strategy, as indefinite kinase blocking is unsustainable. The future likely lies in BTK degraders, a new drug class that eliminates the target protein entirely, offering a novel approach to overcoming resistance instead of just inhibiting the protein.

While second-generation BTK inhibitors are clinically similar, the next major advance in combination therapy may come from the BCL2 inhibitor component. The newer agent sonrotoclax is potentially more potent and selective than venetoclax, which could lead to superior efficacy and tolerability in future regimens.

Non-covalent BTK inhibitors like pirtobrutinib are currently approved for use after covalent BTK inhibitors fail. Moving them to the frontline setting, as studied in BRUIN-313, disrupts the established treatment pathway and creates uncertainty for managing relapsed disease, as the standard 'next step' is removed.

Current oral BTK/BCL-2 inhibitor combinations for CLL have hit an MRD clearance "wall" of 35-50%. By upgrading the BCL-2 inhibitor to the more potent somatoclax, combined with zanubrutinib, MRD clearance rates nearly double to 98%, demonstrating that improving the BCL-2 component is key to achieving deeper remissions.

Despite advancements from first-generation (ibrutinib) to second-generation (acalabrutinib) BTK inhibitors, a consistent pattern emerges: the rate of complete responses plateaus around 36% over time. This suggests a potential biological limit for this class of drugs when used as monotherapy in CLL.

Platelet aggregation studies show riluzobrutinib does not impair platelet function. This unique profile suggests it may not need to be stopped before surgery, avoiding the risk of a perilous drop in platelet counts for ITP patients—a key differentiator from other BTK inhibitors.

Improved T-cell function in CLL patients on BTK inhibitors is probably a result of the substantial reduction in disease burden, allowing the immune system to normalize. This effect is seen across different BTK inhibitors, challenging the older hypothesis that it was a specific off-target effect (ITK inhibition) of ibrutinib.

Pirtobrutinib's reduced side effects, like atrial fibrillation, stem from its precise targeting of BTK with minimal 'binding promiscuity' to other kinases. This makes it a safer option for patients who have already been on a less-targeted BTK inhibitor.

While the continuous BTK inhibitor zanubrutinib showed longer progression-free survival, this efficacy came with a significant safety trade-off. It led to a 47% rate of serious adverse events compared to 24% for the fixed-duration acalabrutinib-venetoclax combination in the indirect analysis.